Summary
The COVID pandemic can be seen as an experiment done with the entirety of humankind (as almost everybody has been or will get infected with SARS-CoV-2). It will therefore have the best coverage over the widest variation possible and is therefore ideally suited to study the effects of infections with SARS-CoV-2 on large quantities of heterogeneous individuals. In our project, we will focus on neurodegenerative diseases (NDDs), namely Alzheimer and Parkinsonism, as the NCDs under investigation.
COMMUTE is a project characterized by the intelligent combination of two fundamentally different approaches: a hypotheses-free, data-driven approach is building on available big data and the application of cutting edge AI/ML technologies to answer the question, whether infection by SARS-CoV-2 causes effects that result in a higher risk for the development of NDDs at population-level. Complementary to that, a hypothesis-driven, knowledge-based approach leverages the substantial knowledge in the scientific community working on NDDs on the putative comorbidity mechanisms linking COVID and neurodegeneration. Both approaches are informing and supporting each other through an intensive crosstalk between computational and experimental biology methods.
Understanding comorbidity between COVID and NDDs at causal level is the first goal of the COMMUTE project. The second goal is the translation of the actionable insights into personalized health applications.
On the AI/ML side, the targeted outcome for translation into practice is a set of qualified biomarkers and predictive features that will be used for an AI-powered, model-generated recommender system that will allow for individualized risk assessment and personalized recommendations. On the side of the biomedical assay systems, COMMUTE will use cell-based assays based on clear pathophysiology mechanism understanding for drug-repurposing screenings in collaboration with REMEDI4ALL, the largest of the EU drug repurposing platforms.
COMMUTE is a project characterized by the intelligent combination of two fundamentally different approaches: a hypotheses-free, data-driven approach is building on available big data and the application of cutting edge AI/ML technologies to answer the question, whether infection by SARS-CoV-2 causes effects that result in a higher risk for the development of NDDs at population-level. Complementary to that, a hypothesis-driven, knowledge-based approach leverages the substantial knowledge in the scientific community working on NDDs on the putative comorbidity mechanisms linking COVID and neurodegeneration. Both approaches are informing and supporting each other through an intensive crosstalk between computational and experimental biology methods.
Understanding comorbidity between COVID and NDDs at causal level is the first goal of the COMMUTE project. The second goal is the translation of the actionable insights into personalized health applications.
On the AI/ML side, the targeted outcome for translation into practice is a set of qualified biomarkers and predictive features that will be used for an AI-powered, model-generated recommender system that will allow for individualized risk assessment and personalized recommendations. On the side of the biomedical assay systems, COMMUTE will use cell-based assays based on clear pathophysiology mechanism understanding for drug-repurposing screenings in collaboration with REMEDI4ALL, the largest of the EU drug repurposing platforms.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101136957 |
| Start date: | 01-12-2023 |
| End date: | 30-11-2027 |
| Total budget - Public funding: | 7 280 986,25 Euro - 7 280 986,00 Euro |
Cordis data
Original description
The COVID pandemic can be seen as an experiment done with the entirety of humankind (as almost everybody has been or will get infected with SARS-CoV-2). It will therefore have the best coverage over the widest variation possible and is therefore ideally suited to study the effects of infections with SARS-CoV-2 on large quantities of heterogeneous individuals. In our project, we will focus on neurodegenerative diseases (NDDs), namely Alzheimer and Parkinsonism, as the NCDs under investigation.COMMUTE is a project characterized by the intelligent combination of two fundamentally different approaches: a hypotheses-free, data-driven approach is building on available big data and the application of cutting edge AI/ML technologies to answer the question, whether infection by SARS-CoV-2 causes effects that result in a higher risk for the development of NDDs at population-level. Complementary to that, a hypothesis-driven, knowledge-based approach leverages the substantial knowledge in the scientific community working on NDDs on the putative comorbidity mechanisms linking COVID and neurodegeneration. Both approaches are informing and supporting each other through an intensive crosstalk between computational and experimental biology methods.
Understanding comorbidity between COVID and NDDs at causal level is the first goal of the COMMUTE project. The second goal is the translation of the actionable insights into personalized health applications.
On the AI/ML side, the targeted outcome for translation into practice is a set of qualified biomarkers and predictive features that will be used for an AI-powered, model-generated recommender system that will allow for individualized risk assessment and personalized recommendations. On the side of the biomedical assay systems, COMMUTE will use cell-based assays based on clear pathophysiology mechanism understanding for drug-repurposing screenings in collaboration with REMEDI4ALL, the largest of the EU drug repurposing platforms.
Status
SIGNEDCall topic
HORIZON-HLTH-2023-DISEASE-03-07Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Coördinator)
-
| ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
-
| BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (BSC)
-
| FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER
-
| KAIRNTECH
-
| KAIRNTECH DEUTSCHLAND UG HAFTUNGSBESCHRANKT
-
| KOBENHAVNS UNIVERSITET
-
| LUXEMBOURG INSTITUTE OF HEALTH
-
| PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT
-
| STICHTING VUMC
-
| THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
-
| UNIVERSITAT WIEN
-
| UNIVERSITE DU LUXEMBOURG